Opioid Induced Constipation Treatment Market Is Projected to Record Sluggish CAGR of 31.2% Throughout 2015-2023
Takeda Pharmaceuticals Company, Ltd., with its approved drug Amitiza, holds a majority share in the global market for opioid induced constipation treatment. In 2014 the top three players - Takeda, Valeant Pharmaceuticals International, Ltd., and Boehringer Ingelheim – operated on a collective share of 91.8% of the global market.
View full press release